News

Biofil Chemicals and Pharmaceuticals Limited submitted a certificate to the BSE Limited and National Stock Exchange of India Limited under Regulation 74(5) of the Securities and Exchange Board of India (Depository and Participants) Regulations, 2018, for the quarter ended September 30, 2026, confirming the dematerialization of securities and related actions by Ankit Consultancy Private Limited, the company`s registrar and share transfer agent.

Biofil Chemicals and Pharmaceuticals Limited announced that members approved the continuation of Ashok Kumar Ramawat`s directorship as a Non-Executive Independent Director, despite him attaining the age of 75 years, at the company`s 41st Annual General Meeting held on September 23, 2026. Mr. Ramawat, who holds DIN: 08818263, has completed a Bachelor`s degree in Science and possesses 46 years of experience in the pharmaceuticals industry, and his directorship will continue until September 27, 2027, when he reaches the age of 75.

Biofil Chemicals and Pharmaceuticals Limited will close its trading window for designated persons, their immediate relatives, and connected persons starting October 1, 2026, to consider unaudited financial results for the quarter ended September 30, 2026, in compliance with SEBI regulations. The trading window will reopen 48 hours after the results are declared to the stock exchanges, and a board meeting to consider the results will be scheduled at a later date.

Biofil Chemicals & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 11 August 2026.

Net profit of Biofil Chemicals & Pharmaceuticals rose 5.00% to Rs 0.21 crore in the quarter ended March 2026 as against Rs 0.20 crore during the previous quarter ended March 2025. Sales declined 9.34% to Rs 7.57 crore in the quarter ended March 2026 as against Rs 8.35 crore during the previous quarter ended March 2025.For the full year,net profit rose 398.21% to Rs 2.79 crore in the year ended March 2026 as against Rs 0.56 crore during the previous year ended March 2025. Sales declined 14.97% to Rs 28.40 crore in the year ended March 2026 as against Rs 33.40 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales7.578.35 -9 28.4033.40 -15 OPM %5.681.32 -2.322.54 - PBDT0.540.34 59 3.731.12 233 PBT0.470.26 81 3.460.74 368 NP0.210.20 5 2.790.56 398 Powered by Capital Market - Live News